{"id":"genhevac-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1160385","moleculeType":"Small molecule","molecularWeight":"182.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GenHevac-B uses a recombinant hepatitis B surface antigen formulation to generate or enhance cellular and humoral immune responses in patients with chronic hepatitis B infection. By priming the immune system against HBsAg, the vaccine aims to facilitate viral clearance and functional cure in chronically infected individuals who have failed to mount adequate spontaneous immune responses.","oneSentence":"GenHevac-B is a therapeutic hepatitis B vaccine designed to boost immune response in chronically infected patients by presenting hepatitis B surface antigen (HBsAg) to stimulate T-cell and B-cell immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:52.665Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection (therapeutic vaccination)"}]},"trialDetails":[{"nctId":"NCT01698866","phase":"PHASE4","title":"Low Grade Lymphoma","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2012-07","conditions":"Indolent Lymphoproliferative Disorders","enrollment":40},{"nctId":"NCT00670839","phase":"PHASE3","title":"Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2008-05","conditions":"Hepatitis B, HIV Infection","enrollment":178},{"nctId":"NCT00480792","phase":"PHASE3","title":"Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2007-06","conditions":"HIV Infections","enrollment":437},{"nctId":"NCT01027065","phase":"PHASE1, PHASE2","title":"Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients","status":"UNKNOWN","sponsor":"Cytheris SA","startDate":"2009-12","conditions":"Chronic Hepatitis B","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sanofi Pasteur MSD"],"phase":"phase_3","status":"active","brandName":"GenHevac-B","genericName":"GenHevac-B","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Biologic","firstApprovalDate":"","aiSummary":"GenHevac-B is a therapeutic hepatitis B vaccine designed to boost immune response in chronically infected patients by presenting hepatitis B surface antigen (HBsAg) to stimulate T-cell and B-cell immunity. Used for Chronic hepatitis B infection (therapeutic vaccination).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}